• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 13th August 2013

Special Issue of EJHE Examines Progress on Refinement of the EQ-5D

Just released online [open access] is a special issue of the European Journal of Health Economics on the development of new research methods for the valuation of EQ-5D-5L. It is co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Just released online [open access] is a special issue of the European Journal of Health Economics on the development of new research methods for the valuation of EQ-5D-5L. It is co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe of the University of Groningen/University Medical Center Groningen. Both are active members of the EuroQol Group; Nancy chairs its Executive Committee.

Just released online [open access] is a special issue of the European Journal of Health Economics[1] on the development of new research methods for the valuation of EQ-5D-5L. It is co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe of the University of Groningen/University Medical Center Groningen. Both are active members of the EuroQol Group; Nancy chairs its Executive Committee. 

The EQ-5D is arguably the best known and most commonly used generic measure of health status worldwide. Experience has provided evidence of both merits and limitations. One central concern is whether the three-level EQ-5D is sensitive enough to capture important aspects of health in certain disease areas. The EuroQol Group has undertaken an ambitious research and development program to address this, including the development of a five-level version of the EQ-5D, the EQ-5D-5L. This initiative is an opportunity to both advance methods for health state valuation and to offer a common protocol that can be followed in all countries.

Part of the EuroQol programme includes research aimed at overcoming well known problems and limitations with the “time trade off” (TTO) approach that is used to value the EQ-5D-5L. In particular, “lead” and “lag” time TTO approaches were investigated as potential methods for overcoming issues in valuing health states considered to be worse than being dead. The research also includes testing and evaluating preferences data for the EQ-5D-5L, which is more complex than its three-level predecessor for lay participants asked to value health states.

The papers in this issue report on this ambitious program of research. They draw together the findings from a multicountry pilot study to test an initial version of the study protocol and related experimentation with aspects of the methods in that protocol. Specifically, they compare the use of lead and lag time TTO; explore the effect on valuation of changing the length of duration of health states; examine the use of discrete choice methods in EQ-5D-5L valuation and explore the effect of different modes of data collection.

The research in this supplemental issue already has had an impact in refining and improving the methods in the Euroqol  Group’s final international protocol for producing EQ-5D-5L data sets. Studies based on this protocol are soon to be completed in Canada, China, England, The Netherlands and Spain; value sets for each country to be reported later this year. Value set studies are also about to commence in a range of other countries, including Germany, Japan, Hong Kong, Singapore, South Korea, Taiwan, Thailand and Uruguay. Other countries also have expressed interest. This fully documented research protocol will help ensure that studies undertaken meet a high standard. Moreover, the consistency of design and methods it promotes will allow for valid international comparisons of the EQ-5D-5L valuation data.

Research involving OHE’s Nancy Devlin and Koonal Shah is featured in several papers in this issue. For example, the article by Shah et al shows that the quality of TTO data clearly is affected by the mode of data collection: computer-assisted, one-on-one, interviewer-led interviews are superior to self-completion in a group setting. Nancy Devlin was involved in three of the studies on TTO: lead versus lag time, comparisons of lead/lag time to classic TTO approaches, and the use of visual aids in gathering reliable TTO valuations.

Previous research by Nancy and Koonal, available on this website as an OHE Research Paper:  

Download Devlin, N, Buckingham, K., Shah, K., Tsuchiya, A., Tilling, C., Wilkinson, G. and Van Hoot, B. (2010) A comparison of alternative variants of the lead and lag time TTO. Research Paper 10/02. London: Office of Health Economics.  [This has been published as: Devlin, N., Buckingham, K., Shah, K.K., Tsuchiya, A., Tilling, C., Wilkinson, G. and van Hout, B. (2013) A comparison of alternative variants of the lead and lag time TTO. Health Economics. 22(5), 517-532.]

See also Nancy’s recent presentations about the EuroQol Group and efforts worldwide to develop and apply EQ-5D measures on OHE’s SlideShare site. Her recent visits to Singapore and Sweden have been reported in this blog. 


[1] European Journal of Health Economics. (2013) 14(1 Suppl). Open access.
 
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes

Related News

Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!